
Alzamend Neuro and Mass General Launch Phase II Trial of AL001 for Alzheimer’s
Alzamend Neuro, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, announced its partnership with Massachusetts General Hospital (Mass General) to conduct a Phase II clinical trial of…












